Selective Serotonin Reuptake Inhibitors

Selective serotonin re-uptake inhibitors or serotonin-specific reuptake inhibitors (SSRIs) are a class of drugs that are typically used as antidepressants in the treatment of major depressive disorder and anxiety disorders.
DrugDrug NameDrug Indication
DB00476Duloxetine**Indicated** for: 1) Management of Major Depressive Disorder.[label] 2) Management of Generalized Anxiety Disorder.[label] 3) Management of diabetic peripheral neuropathy.[label] 4) Management of fibromyalgia.[label] 5) Management of chronic musculoskeletal pain.[label] 6) Management of osteoarthritis of the knee in adults.[L6364] 7) Management of chronic lower back pain in adults.[L6364] 8) Management of stress urinary incontinence in adult women.[L6367] **Off-label** uses include: 1) Management of chemotherapy-induced peripheral neuropathy.[A178603] 2) Management of stress urinary incontinence in adult men after prostatectomy until recovery is complete.[L6370]
DB01149NefazodoneFor the treatment of depression.
DB06700DesvenlafaxineDesvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label].
DB04896MilnacipranMilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia in patients that are 18 years old or above [F3925]. While milnacipran may be used for the treatment of major depressive disorder (MDD), it is only recommended in adult patients who are 18 years old or above [F3922] due to an increased risk for suicidal ideation, thinking, and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder (MDD) and other psychiatric disorders. Some regional prescribing information notes that the use of the medication is specifically for the short-term symptomatic relief of MDD [F3919]. Nevertheless, it is important to note that the regulatory approval of and/or indications listed here for milnacipran may or may not exist and/or vary greatly between regions and nations [F3928, F3934].
DB08918LevomilnacipranLevomilnacipran is a serotonin and norepinephrine reuptake inhibitor and is indicated for the treatment of major depressive disorder (MDD).
DB04884DapoxetineFor the treatment of premature ejaculation.
DB08953IndalpineNot Available
DB00656TrazodoneTrazodone is indicated for the treatment of major depressive disorder (MDD).[L3484] It has been used off-label for adjunct therapy in alcohol dependence, and off-label to treat anxiety and insomnia.[L3484] It may also be used off-label to treat symptoms of dementia, Alzheimer’s disease, schizophrenia, eating disorders, and fibromyalgia due to its effects on various neurotransmitter receptors.[A31634]
DB00176FluvoxamineIndicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) [FDA Label]. Has also been used in the management of bulimia nervosa [A250].
DB00215CitalopramFor the treatment of depression, as indicated by the FDA label [FDA label]. Off-label indications include but are not limited to: treatment of sexual dysfunction, post-stroke behavioural changes, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA label], [A321], [A322], [A323], [A324], [A174406], [A174409], [A174412].
DB00472FluoxetineFluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present.[L7664] Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder, and treatment resistant depression.[L7664]
DB00715ParoxetineParoxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder.[L3358] One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause.[L7703] Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).[A1093,A181754,A181904]
DB01104SertralineFor the management of major depressive disorder (MDD), posttraumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD) with or without agoraphobia, premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD) [FDA Label]. It may be used for premature ejaculation and vascular headaches as off-label indications.
DB01175EscitalopramEscitalopram is indicated for both acute and maintenance treatment of major depressive disorder (MDD) and for the acute treatment of generalized anxiety disorder (GAD).[L8513] It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.[L8516]
DB04832ZimelidineFor the treatment of depression.
DB13233AlaproclateNot Available
DB12693RitanserinNot Available
DB01105SibutramineFor the treatment of obesity.
DB06731SeproxetineNot Available
DrugDrug NameTargetType
DB00476DuloxetineSodium-dependent serotonin transportertarget
DB00476DuloxetineSodium-dependent dopamine transportertarget
DB00476DuloxetineSodium-dependent noradrenaline transportertarget
DB00476DuloxetineCytochrome P450 1A2enzyme
DB00476DuloxetineCytochrome P450 2D6enzyme
DB00476DuloxetineCytochrome P450 2C9enzyme
DB00476DuloxetineSerum albumincarrier
DB00476Duloxetinealpha1-acid glycoproteincarrier
DB00476DuloxetineP-glycoprotein 1transporter
DB01149Nefazodone5-hydroxytryptamine receptor 2Atarget
DB01149NefazodoneSodium-dependent serotonin transportertarget
DB01149NefazodoneSodium-dependent noradrenaline transportertarget
DB01149NefazodoneAlpha-1A adrenergic receptortarget
DB01149NefazodoneAlpha-1B adrenergic receptortarget
DB01149NefazodoneCytochrome P450 3A4enzyme
DB01149NefazodoneCytochrome P450 2D6enzyme
DB01149NefazodoneSodium-dependent dopamine transportertarget
DB01149NefazodoneAlpha-2A adrenergic receptortarget
DB01149Nefazodone5-hydroxytryptamine receptor 1Atarget
DB01149NefazodoneCYP2B proteinenzyme
DB01149NefazodoneP-glycoprotein 1transporter
DB01149Nefazodone5-hydroxytryptamine receptor 2Ctarget
DB01149NefazodonePotassium voltage-gated channel subfamily H member 2target
DB01149NefazodoneCYP3Aenzyme
DB01149NefazodoneSolute carrier organic anion transporter family member 1B3transporter
DB01149NefazodoneSolute carrier organic anion transporter family member 2B1transporter
DB01149NefazodoneBile salt export pumptransporter
DB06700DesvenlafaxineCytochrome P450 3A4enzyme
DB06700DesvenlafaxineSodium-dependent serotonin transportertarget
DB06700DesvenlafaxineSodium-dependent noradrenaline transportertarget
DB06700DesvenlafaxineCytochrome P450 2D6enzyme
DB06700DesvenlafaxineSodium-dependent dopamine transportertarget
DB04896MilnacipranSodium-dependent serotonin transportertarget
DB04896MilnacipranSodium-dependent noradrenaline transportertarget
DB04896MilnacipranNMDA receptortarget
DB04896MilnacipranCytochrome P450 3A4enzyme
DB08918LevomilnacipranCytochrome P450 3A4enzyme
DB08918LevomilnacipranCytochrome P450 2C8enzyme
DB08918LevomilnacipranCytochrome P450 2C19enzyme
DB08918LevomilnacipranCytochrome P450 2D6enzyme
DB08918LevomilnacipranCytochrome P450 2J2enzyme
DB08918LevomilnacipranSodium-dependent serotonin transportertarget
DB08918LevomilnacipranSodium-dependent noradrenaline transportertarget
DB08918LevomilnacipranP-glycoprotein 1transporter
DB04884Dapoxetine5-hydroxytryptamine receptor 1Atarget
DB04884Dapoxetine5-hydroxytryptamine receptor 1Btarget
DB04884Dapoxetine5-hydroxytryptamine receptor 2Ctarget
DB04884DapoxetineCytochrome P450 3A4enzyme
DB04884DapoxetineCytochrome P450 2D6enzyme
DB08953IndalpineCytochrome P450 3A4enzyme
DB00656Trazodone5-hydroxytryptamine receptor 2Atarget
DB00656TrazodoneSodium-dependent serotonin transportertarget
DB00656TrazodoneAlpha-1A adrenergic receptortarget
DB00656TrazodoneAlpha-2A adrenergic receptortarget
DB00656TrazodoneHistamine H1 receptortarget
DB00656Trazodone5-hydroxytryptamine receptor 1Atarget
DB00656TrazodoneCytochrome P450 2D6enzyme
DB00656TrazodoneCytochrome P450 3A4enzyme
DB00656Trazodone5-hydroxytryptamine receptor 2Ctarget
DB00656TrazodoneCytochrome P450 3A5enzyme
DB00656TrazodoneCytochrome P450 3A7enzyme
DB00656TrazodoneP-glycoprotein 1transporter
DB00656Trazodone5-hydroxytryptamine receptor 1Ctarget
DB00176FluvoxamineSodium-dependent serotonin transportertarget
DB00176FluvoxamineCytochrome P450 1A2enzyme
DB00176FluvoxamineCytochrome P450 2D6enzyme
DB00176FluvoxamineCytochrome P450 2C9enzyme
DB00176FluvoxamineCytochrome P450 2C19enzyme
DB00176FluvoxamineCytochrome P450 1A1enzyme
DB00176FluvoxamineCytochrome P450 3A4enzyme
DB00176FluvoxamineCYP3Aenzyme
DB00176FluvoxamineP-glycoprotein 1transporter
DB00176FluvoxamineCytochrome P450 2B6enzyme
DB00176FluvoxaminePotassium voltage-gated channel subfamily H member 2target
DB00176FluvoxamineBile salt export pumptransporter
DB00215CitalopramSodium-dependent serotonin transportertarget
DB00215CitalopramCytochrome P450 2C19enzyme
DB00215CitalopramCytochrome P450 2D6enzyme
DB00215CitalopramCytochrome P450 3A4enzyme
DB00215CitalopramP-glycoprotein 1transporter
DB00215CitalopramCytochrome P450 1A2enzyme
DB00215CitalopramHistamine H1 receptortarget
DB00472FluoxetineSodium-dependent serotonin transportertarget
DB00472FluoxetineCytochrome P450 2C9enzyme
DB00472FluoxetineCytochrome P450 2D6enzyme
DB00472FluoxetineCYP2B proteinenzyme
DB00472FluoxetineCytochrome P450 1A2enzyme
DB00472FluoxetineCytochrome P450 3A4enzyme
DB00472FluoxetineCytochrome P450 2C19enzyme
DB00472FluoxetineP-glycoprotein 1transporter
DB00472FluoxetineCytochrome P450 2B6enzyme
DB00472FluoxetineCytochrome P450 3A5enzyme
DB00472FluoxetineSerum albumincarrier
DB00472FluoxetineAlpha-1-acid glycoprotein 1carrier
DB00472FluoxetinePotassium voltage-gated channel subfamily H member 2target
DB00472Fluoxetine5-hydroxytryptamine receptor 2Ctarget
DB00472FluoxetineCyclin-dependent kinases regulatory subunit 1target
DB00472FluoxetineNeuronal acetylcholine receptor subunit alpha-2target
DB00472FluoxetineNeuronal acetylcholine receptor subunit alpha-3target
DB00472FluoxetineNeuronal acetylcholine receptor subunit beta-4target
DB00715ParoxetineSodium-dependent serotonin transportertarget
DB00715ParoxetineSodium-dependent noradrenaline transportertarget
DB00715Paroxetine5-hydroxytryptamine receptor 2Atarget
DB00715ParoxetineCytochrome P450 2D6enzyme
DB00715ParoxetineCytochrome P450 2C9enzyme
DB00715ParoxetineP-glycoprotein 1transporter
DB00715ParoxetineCytochrome P450 2B6enzyme
DB00715ParoxetineCytochrome P450 1A2enzyme
DB00715ParoxetineCytochrome P450 3A4enzyme
DB00715ParoxetineAlpha-1 adrenergic receptorstarget
DB00715ParoxetineAlpha-2 adrenergic receptorstarget
DB00715ParoxetineBeta adrenergic receptortarget
DB00715ParoxetineDopamine D2 receptortarget
DB00715ParoxetineHistamine H1 receptortarget
DB00715ParoxetineSerotonin Receptorstarget
DB00715ParoxetineMuscarinic acetylcholine receptortarget
DB00715Paroxetine5-hydroxytryptamine receptor 2Btarget
DB00715ParoxetineD(1) dopamine receptortarget
DB00715ParoxetineCytochrome P450 2C19enzyme
DB01104SertralineSodium-dependent serotonin transportertarget
DB01104SertralineCytochrome P450 2B6enzyme
DB01104SertralineCytochrome P450 2C19enzyme
DB01104SertralineCytochrome P450 2C9enzyme
DB01104SertralineCytochrome P450 2D6enzyme
DB01104SertralineSodium-dependent dopamine transportertarget
DB01104SertralineCYP2B proteinenzyme
DB01104SertralineCytochrome P450 3A4enzyme
DB01104SertralineAmine oxidase [flavin-containing] Benzyme
DB01104SertralineAmine oxidase [flavin-containing] Aenzyme
DB01104SertralineP-glycoprotein 1transporter
DB01104SertralineSerum albumincarrier
DB01104SertralineSigma receptortarget
DB01175EscitalopramSodium-dependent serotonin transportertarget
DB01175EscitalopramCytochrome P450 3A4enzyme
DB01175EscitalopramCytochrome P450 2D6enzyme
DB01175EscitalopramSodium-dependent dopamine transportertarget
DB01175EscitalopramSodium-dependent noradrenaline transportertarget
DB01175EscitalopramMuscarinic acetylcholine receptor M1target
DB01175EscitalopramHistamine H1 receptortarget
DB01175EscitalopramCytochrome P450 2C19enzyme
DB01175EscitalopramMonoamine oxidaseenzyme
DB01175EscitalopramP-glycoprotein 1transporter
DB01175Escitalopram5-hydroxytryptamine receptor 1Atarget
DB01175Escitalopram5-hydroxytryptamine receptor 2Atarget
DB01175Escitalopram5-hydroxytryptamine receptor 2Ctarget
DB01175EscitalopramAlpha-1 adrenergic receptorstarget
DB01175EscitalopramAlpha-2 adrenergic receptorstarget
DB01175EscitalopramDopamine D2 receptortarget
DB04832ZimelidineSodium-dependent serotonin transportertarget
DB04832ZimelidineP-glycoprotein 1transporter
DB04832ZimelidineAmine oxidase [flavin-containing] Btarget
DB04832ZimelidineAmine oxidase [flavin-containing] Atarget
DB04832ZimelidineCytochrome P450 3A4enzyme
DB12693Ritanserin5-hydroxytryptamine receptor 2Atarget
DB12693RitanserinCytochrome P450 2D6enzyme
DB01105SibutramineSodium-dependent serotonin transportertarget
DB01105SibutramineSodium-dependent noradrenaline transportertarget
DB01105SibutramineCytochrome P450 3A4enzyme
DB01105SibutramineSodium-dependent dopamine transportertarget
DB06731SeproxetineCytochrome P450 3A5enzyme
DB06731SeproxetineCytochrome P450 3A7enzyme
DB06731SeproxetineCytochrome P450 2C9enzyme
DB06731SeproxetineCytochrome P450 2C19enzyme
DB06731SeproxetineCytochrome P450 3A4enzyme